Abstract

Constitutive activation of NF-kappa B is an emerging hallmark of various types of tumors including breast, colon, pancreatic, ovarian, and melanoma. In melanoma cells, the basal expression of the CXC chemokine, CXCL1, is constitutively up-regulated. This up-regulation can be attributed in part to constitutive activation of NF-kappa B. Previous studies have shown an elevated basal I kappa B kinase (IKK) activity in Hs294T melanoma cells, which leads to an increased rate of I kappa B phosphorylation and degradation. This increase in I kappa B-alpha phosphorylation and degradation leads to an approximately 19-fold higher nuclear localization of NF-kappa B. However, the upstream IKK kinase activity is up-regulated by only about 2-fold and cannot account for the observed increase in NF-kappa B activity. We now demonstrate that NF-kappa B-inducing kinase (NIK) is highly expressed in melanoma cells, and IKK-associated NIK activity is enhanced in these cells compared with the normal cells. Kinase-dead NIK blocked constitutive NF-kappa B or CXCL1 promoter activity in Hs294T melanoma cells, but not in control normal human epidermal melanocytes. Transient overexpression of wild type NIK results in increased phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2), which is inhibited in a concentration-dependent manner by PD98059, an inhibitor of p42/44 MAPK. Moreover, the NF-kappa B promoter activity decreased with overexpression of dominant negative ERK expression constructs, and EMSA analyses further support the hypothesis that ERK acts upstream of NF-kappa B and regulates the NF-kappa B DNA binding activity. Taken together, our data implicate involvement of I kappa B kinase and MAPK signaling cascades in NIK-induced constitutive activation of NF-kappa B.

Highlights

  • Constitutive activation of NF-␬B is an emerging hallmark of various types of tumors including breast, colon, pancreatic, ovarian, and melanoma

  • In this study, using various melanoma cell lines, we demonstrate that NF-␬B-inducing kinase (NIK) basal expression as well as IKK-associated NIK activity is higher in melanoma cells compared with normal melanocytes

  • A Kinase-deficient Mutant of NIK Inhibits the NF-␬B and CXCL1-dependent Gene Expression—Previously, we have shown that an elevated constitutive I␬B kinase activity in Hs294T melanoma cells is responsible for higher NF-␬B activity due to higher I␬B-␣ phosphorylation and degradation

Read more

Summary

Introduction

Constitutive activation of NF-␬B is an emerging hallmark of various types of tumors including breast, colon, pancreatic, ovarian, and melanoma. The basal expression of the CXC chemokine, CXCL1, is constitutively up-regulated. Previous studies have shown an elevated basal I␬B kinase (IKK) activity in Hs294T melanoma cells, which leads to an increased rate of I␬B phosphorylation and degradation. Kinase-dead NIK blocked constitutive NF-␬B or CXCL1 promoter activity in Hs294T melanoma cells, but not in control normal human epidermal melanocytes. We have previously shown that CXCL1 transcription is constitutively activated in the human malignant melanoma cell line, Hs294T, through interaction of the HMG1 (Y), Sp1, NF-␬B, and IUR elements in the promoter/enhancer of the CXCL1 gene [5, 6]. A number of recent studies of transient overexpression have suggested that some mitogen-activated protein kinase kinase kinases, including NF-␬B-inducing enzyme (NIK) and MEKK1–3, are involved in the activation of the IKK complex [16, 21,22,23].

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.